Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Other Operating Expenses (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Other Operating Expenses for 5 consecutive years, with $750000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 30.89% year-over-year to $750000.0, compared with a TTM value of $3.9 million through Dec 2025, down 10.99%, and an annual FY2025 reading of $3.9 million, down 10.99% over the prior year.
  • Other Operating Expenses was $750000.0 for Q4 2025 at Aligos Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.6 million in Q1 2024 and bottomed at -$225000.0 in Q2 2021.
  • Average Other Operating Expenses over 5 years is $675600.0, with a median of $797500.0 recorded in 2022.
  • The sharpest move saw Other Operating Expenses crashed 104.5% in 2022, then soared 20140.0% in 2023.
  • Year by year, Other Operating Expenses stood at $176000.0 in 2021, then skyrocketed by 380.11% to $845000.0 in 2022, then crashed by 71.12% to $244000.0 in 2023, then soared by 134.84% to $573000.0 in 2024, then skyrocketed by 30.89% to $750000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for ALGS at $750000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.2 million in Q2 2025.